Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
ScemblixⓇ - BCR-ABL inhibitor
Company overview
NCT04971226 ASC4FIRST (CABL001J12301)
Chronic myeloid leukemia, 1st line
Phase 3
Major Molecular Response (MMR) at week 48
Arm 1: asciminib 80 mg QD
Arm 2: Investigator selected TKI including one of the below treatments:
- Imatinib 400 mg QD
Financial review
Conclusions
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Cardiovascular, Renal
and Metabolic
Immunology
Neuroscience
> Oncology
Other
Global Health
Abbreviations
Indication
Phase
Patients
402
Primary
Outcome
Measures
Arms
Intervention
Target Patients
References
- Nilotinib 300 mg BID
- Dasatinib 100 mg QD
- Bosutinib 400 mg QD
Patients with newly diagnosed philadelphia chromosome positive chronic
myelogenous leukemia in chronic phase
Readout
Milestone(s)
2024 (actual)
Publication
TBD
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
76View entire presentation